KAS
MLYS icon

Kemnay Advisory Services’s Mineralys Therapeutics MLYS Stock Holding History

Kemnay Advisory Services’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.1K Buy
+597
New +$16.4K ﹤0.01% 862

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Kemnay Advisory Services's MLYS Position: Q2 2026 in Review

Kemnay Advisory Services opened a new position in Mineralys Therapeutics (MLYS) in Q2 2026: 597 shares worth $16.1K. The stake represents ﹤0.01% of the portfolio and ranks #862 among its holdings.

224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Kemnay Advisory Services held 597 shares of Mineralys Therapeutics worth $16.1K as of Q2 2026.
  • Mineralys Therapeutics was a new Kemnay Advisory Services position in Q2 2026.
  • Mineralys Therapeutics made up ﹤0.01% of Kemnay Advisory Services's portfolio in Q2 2026, its #862 holding.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Kemnay Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.